Pfizer Medical Information

Health Care Professionals Log In

Sign Up for RELISTOR Updates

Gain access to additional content on the RELISTOR Web site and receive updates. You’ll also get at no charge, unlimited access to:

  • The 5–Minute Clinical Consult
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets

Register Now
Nurses Resources


The usual schedule is one dose every other day, as needed, but no more frequently than one dose in a 24-hour period.1

RECOMMENDED DOSE1

Patients whose weight falls outside of these ranges should be dosed at 0.15 mg/kg. The injection volume for these patients should be calculated using one of the following:

  • Multiply the patient weight in pounds by 0.0034 and round up the volume to the nearest 0.1 mL
  • Multiply the patient weight in kilograms by 0.0075 and round up the volume to the nearest 0.1 mL
  • RELISTOR is available in single-use vials for subcutaneous injection1
  • No dose adjustment required in elderly patients1
  • No dose adjustment required in patients with mild or moderate renal or hepatic impairment1
  • Dose reduction by one half is recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min)1
  • The effect of severe hepatic impairment or end-stage renal impairment requiring dialysis on the pharmacokinetics of methylnaltrexone has not been studied1


Patient and caregiver injection tools

RELISTOR eDetail

Participate in an interactive program about treating OIC in patients with advanced illness who are receiving palliative care and build a Virtual Sales Brochure

Indication

RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR
beyond 4 months has not been studied.

Important Safety Information for RELISTOR

  • RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
  • If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
  • Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
  • Use of RELISTOR has not been studied in patients with peritoneal catheters
  • The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
  • Safety and efficacy of RELISTOR have not been established in pediatric patients

Please see the full Prescribing Information.